基于风险分层的急性肾损伤预测模型联合血液灌流治疗脓毒症患者的前瞻性观察性初步研究
该前瞻性、观察性、初步研究纳入2019年5月至12月兰州大学第二医院ICU收治的49例符合Sepsis-3诊断标准的脓毒症患者,以研究组前期建立的AKI早期预警模型评估AKI风险>30%为高风险,30例进入观察组、19例进入对照组。所有患者接受常规治疗(寻找并处理原发感染灶、使用抗生素及主要器官功能支持),观察组在常规治疗基础上联合血液灌流,每日2.5小时、连续3天。结果显示观察组入ICU 72小时白细胞介素-6显著低于对照组(90.9±38.1 ng/L vs 119.1±41.9 ng/L,P<0.05),ICU住院时间显著缩短(9.77±2.76天 vs 12.47±3.85天,P<0.01),但脂多糖、降钙素原及ICU死亡率(20.0% vs 21.1%,P>0.05)无显著差异,49例均无严重出血事件。作者认为该模型联合血液灌流在理论和临床实践中可行并能缩短ICU住院时间,但不能有效清除炎症介质或降低脓毒症死亡率,仍需大样本、多中心、随机对照研究进一步验证。
要点
- 脓毒症患者按AKI早期预警模型评估AKI风险>30%为高风险,高风险者在常规治疗基础上联合血液灌流每日2.5小时、连续3天。
- 观察组入ICU 72小时白细胞介素-6显著低于对照组(90.9±38.1 ng/L vs 119.1±41.9 ng/L,P<0.05)。
- 观察组ICU住院时间显著短于对照组(9.77±2.76天 vs 12.47±3.85天,P<0.01)。
- 两组ICU死亡率无显著差异(观察组20.0% vs 对照组21.1%,P>0.05),脂多糖和降钙素原在72小时亦无显著差异。
- 49例患者均未发生严重出血事件。
适用人群与场景
- 2019年5月至12月兰州大学第二医院ICU收治、符合Sepsis-3诊断标准的脓毒症患者。
- 以研究组前期建立的AKI早期预警模型评估AKI风险>30%者为高风险,纳入观察组;其余纳入对照组。
- 主要诊断为肺炎,主要致病菌为革兰阴性杆菌[61.2%(30/49)]。
诊断标准与关键阈值
- 符合Sepsis-3诊断标准。
- 采用研究组前期建立的AKI早期预警模型,AKI风险>30%定义为AKI高风险。
处置流程与药物剂量
- 所有患者接受常规治疗,包括寻找并处理原发感染部位、使用抗生素及主要器官功能支持。
- 观察组在常规治疗基础上联合血液灌流治疗,每日2.5小时、连续3天。
红旗征与不能漏的情况
- 记录出血事件;49例患者均无严重出血事件。
研究设计与关键结果
- 前瞻性、观察性、初步研究,纳入49例脓毒症患者,观察组30例(AKI风险>30%)、对照组19例;两组性别、年龄、感染部位、急性生理学与慢性健康状况评分Ⅱ、序贯器官衰竭评估评分、平均动脉压等基线无显著差异,但观察组基线血清肌酐显著高于对照组(112.2±34.4 μmol/L vs 93.4±13.0 μmol/L,P<0.05)。
- 入ICU时及入ICU 24小时,两组白细胞介素-6、脂多糖、降钙素原均无显著差异;随ICU时间延长两组炎症指标呈下降趋势。
- 入ICU 72小时,观察组白细胞介素-6显著低于对照组(90.9±38.1 ng/L vs 119.1±41.9 ng/L,P<0.05),脂多糖和降钙素原两组无显著差异。
- 观察组ICU住院时间显著短于对照组(9.77±2.76天 vs 12.47±3.85天,P<0.01)。
- 两组ICU死亡率无显著差异(观察组20.0% vs 对照组21.1%,P>0.05)。
- 49例患者均无严重出血事件。
证据类型、等级与局限
- 证据类型:前瞻性、观察性、初步研究。
- 作者结论:基于AKI风险分层预测模型联合血液灌流治疗脓毒症患者在理论和临床实践中均可行,可缩短ICU住院时间,但不能有效清除炎症介质或降低脓毒症死亡率。
- 局限:作者指出仍需大样本、多中心、随机对照研究进一步验证。
对床旁实践的改变
- 作者认为,对经AKI早期预警模型评估AKI风险>30%的脓毒症患者,在常规治疗基础上联合血液灌流(每日2.5小时、连续3天)在理论和临床实践中可行,并可缩短ICU住院时间。
- 作者指出,该方案未能有效清除炎症介质或降低脓毒症死亡率,仍需大样本、多中心、随机对照研究进一步验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the efficacy and safety of a risk stratification-based model for prediction of acute kidney injury (AKI) combined with hemoperfusion (HP) in the treatment of patients with sepsis.
METHODS: A prospective, observational, pilot trial was conducted. The patients who met the Sepsis-3 diagnostic criteria admitted to intensive care unit of Lanzhou University Second Hospital from May to December in 2019 were enrolled as the research objects. Through the AKI early warning model established by the research group in the early stage, AKI risk > 30% was defined as AKI high risk. Patients with AKI high risk were enrolled in the observation group, and the remaining patients were enrolled in the control group. All patients were given conventional treatment, including the search and treatment of original infection sites, the use of antibiotics and main organ function support. Patients in the observation group were combined with HP treatment on the basis of conventional treatment, 2.5 hours per day for 3 days. The baseline data of gender, age, infection site, acute physiology and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, mean arterial pressure (MAP) and serum creatinine (SCr) were recorded. The inflammatory indexes such as interleukin-6 (IL-6), lipopolysaccharide (LPS) and procalcitonin (PCT) were detected at ICU admission, 24 hours and 72 hours after ICU admission, and the length of ICU stay, ICU mortality and bleeding were recorded.
RESULTS: Among the 49 patients with sepsis enrolled in this study, the main diagnosis was pneumonia, and Gram-negative (G-) bacilli were the main pathogenic bacteria [61.2% (30/49)]. Among them, 30 patients with AKI risk > 30% were in the observation group, and the remaining 19 patients were in the control group. There was no significant difference in gender, age, infection site, APACHE II score, SOFA score, MAP or other baseline data between the two groups, but the baseline value of SCr in the observation group was significantly higher than that in the control group (μmol/L: 112.2±34.4 vs. 93.4±13.0, P < 0.05). At ICU admission, there was no significant difference in IL-6, LPS or PCT between the two groups. However, with the extension of ICU time, the inflammatory indexes of the two groups showed a downward trend. At 24 hours after ICU admission, there was no significant difference in IL-6, LPS or PCT between the two groups. At 72 hours after ICU admission, IL-6 in the experimental group decreased significantly as compared with the control group (ng/L: 90.9±38.1 vs. 119.1±41.9, P < 0.05), but there was no significant difference in LPS or PCT between the two groups. The length of ICU stay in the experimental group was significantly shorter than that in the control group (days: 9.77±2.76 vs. 12.47±3.85, P < 0.01), but there was no significant difference in the ICU mortality between the experimental group and control group (20.0% vs. 21.1%, P > 0.05). None of the 49 patients had severe bleeding events.
CONCLUSIONS: The application of a risk stratification-based model for prediction of AKI combined with HP in septic patients is feasible both in theory and in clinical practice, and shortens the length of ICU stay, but fails to effectively remove inflammatory mediators or reduce sepsis mortality. A large sample, multicenter, randomized controlled study is still needed for further verification.
参考来源
- Feng F, Chen Y, Chen W, et al. [Application of a risk stratification-based model for prediction of acute kidney injury combined with hemoperfusion in patients with sepsis: a prospective, observational, pilot study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32788015. doi:10.3760/cma.j.cn121430-20200326-00239
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。